News

HDA UK Media And Political Bulletin – 9 November 2017

Media and Political Bulletin

9 November 2017

Media Summary

No-deal Brexit could create meds supply chaos, warns report

PharmaTimes, Selina McKee, 8 November 2017

Pharma Times reports on the findings of an analysis by the Nuffield Trust which state that in the event that the UK fails to reach a deal for Brexit there would be ‘substantial problems’ for the NHS. The think tank points out that leaving without a deal would risk ‘chaotic disruption’ to the medicines supply chain. Furthermore, the report states that even with an exit deal, the failure to agree trade and co-operation arrangements could ‘slow down access to cutting-edge treatments, worsen the risk of vital supplies decaying at the border, and damage medical research in several ways’.

 

EFPIA member survey on the implications of Brexit on medicines supply

ABPI, 9 November 2017

The ABPI have responded to the publication of a new survey of European Federation of Pharmaceutical Industries and Associations (EFPIA) members on the impact of Brexit on medicines supply. The results of the survey underline the importance and scale of the issues that have to be addressed to protect public health. The survey highlighted that medicines used by patients across Europe have integrated supply chains, which include the UK. ​The survey also underlined the following:

  • Over 2,600 final products have some stage of manufacture based in the UK
  • 45 million patient packs are supplied from the UK to other EU-27/EEA countries each month
  • Over 37 million patient packs are supplied from the EU-27/EEA to the UK each month
  • In this context, 45% of EFPIA members expect trade delays if the UK and Europe fell back to WTO rules

The findings of the EFPIA survey were also reported in Reuters. This article quotes EFPIA Director General Nathalie Moll as saying ‘for life-saving and life-improving medicines, the EU and UK cannot afford to wait any longer to ensure that the necessary cooperation on medicines is in place from the day the UK leaves the EU’.

 

Parliamentary Coverage

 

There is no Parliamentary coverage today.

 

Full Coverage

No-deal Brexit could create meds supply chaos, warns report

PharmaTimes, Selina McKee, 8 November 2017

In the event that the UK fails to reach a deal for Brexit there would be “substantial problems” for the NHS, warns a new analysis by independent think tank The Nuffield Trust.

Leaving without a deal would risk a “chaotic disruption” to the medicines supply chain, and a rise in prices that would push hospitals deeper into deficit, according to its briefing, How will our future relationship with the EU shape the NHS?.

It would also obstruct vital procedures provided across the border between Northern Ireland and the Republic of Ireland, and “risk forcing tens of thousands of pensioners to return to seek care in an NHS which has no room for them.”

Furthermore, the report states that even with an exit deal, the failure to agree trade and co-operation arrangements could “slow down access to cutting-edge treatments, worsen the risk of vital supplies decaying at the border, and damage medical research in several ways”.

Such deals will also be essential to ensure that British scientists and doctors can keep working as much as possible with European programmes, like Horizon 2020, which it notes has streamed some 420 million Euros into British health research.

“For many things – from medicine regulation to the rights of NHS staff – there is a way through if deals can be secured. But if negotiations collapse entirely or if political red lines get in the way of future co-operation, patient care will suffer,” noted report author Mark Dayan, Nuffield Trust.

On the plus side, the report does highlight some areas where there could be room for greater flexibility after Brexit, such as the opportunity to free-up current restrictions doctors hours under the Working Time Directive, or removing elements of competition law currently restricting collaboration between NHS organisations.

Parallel trade loss

The briefing was published just days after the Healthcare Distribution Association (HDA) submitted evidence to a Health Select Committee inquiry on Brexit, warning that any disruption to the cross-border flow of medicines has the potential of placing patient safety at risk.

It also emphasised that a so-called ‘hard-Brexit’ and departure from the single market would disable the UK’s right to parallel trade across the European Economic Area (EEA), with an almost immediate impact on patient access to medicines in the UK.

According to the HAD: “There is indeed a higher likelihood of an increased risk of medicine shortages in the UK in the short-term at least, as manufacturers adjust their forecasting, which is often undertaken well in advance of supply. This is because medicine distributors would no longer be able to import vital medicines from the rest of the EEA to service the changing, short-term needs of British patients.

“Moreover, without parallel imports the medicines supply chain will potentially become less resilient in the long term. However good demand forecasting is, there will always be unexpected supply issues, which, without parallel imports, will be harder to address as there will be no way of sourcing product from the EEA to cover the availability gaps.”

The loss of parallel trade would also mean the loss of the direct savings the mechanisms currently affords the NHS, which during the period 2004 – 2009 equated to 986.2 million Euros. “As a result, there is a distinct potential for price rises in NHS medicines as a result of the loss of parallel trade.”

EFPIA member survey on the implications of Brexit on medicines supply

ABPI, 9 November 2017

The ABPI have responded to the publication of a new survey of European Federation of Pharmaceutical Industries and Associations (EFPIA) members on the impact of Brexit on medicines supply.

​The results of the survey (published on the EFPIA website today​)​ underline the importance and scale of the issues that have to be addressed to protect public health. The survey highlighted that medicines used by patients across Europe have integrated supply chains, which include the UK.​

Over 2,600 final products have some stage of manufacture based in the UK

45 million patient packs are supplied from the UK to other EU-27/EEA countries each month

Over 37 million patient packs are supplied from the EU-27/EEA to the UK each month

In this context, 45% of EFPIA members expect trade delays if the UK and Europe fell back to WTO rules.​

Commenting on the survey, Mike Thompson, Chief Executive of The ABPI said:

“This survey highlights not only the sheer scale of pharmaceutical industry integration across Europe – but also how essential this integration is to the successful and timely supply of live-saving treatments to more than 500 million patients.

To avoid significant disruption to the supply, regulation and safety monitoring of medicines for patients in the UK and the EU, agreement and legal certainty on these future arrangements is urgently required.”

HDA UK Media And Political Bulletin – 9 November 2017

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?